Bausch + Lomb (NYSE/TSX: BLCO), a Vaughan, Ontario and Bridgewater, NJ-based health company, acquired AcuFocus, Inc., an Irvine, CA-based ophthalmic medical device company.
The amount of the deal was not disclosed.
With the acquisition, Bausch + Lomb will enhance its surgical portfolio with IC-8 Apthera Intraocular Lens.
Led by Al Waterhouse, president and CEO, AcuFocus delivers small aperture intraocular products to address diverse unmet needs in eye care and help patients achieve their best personal vision. The IC-8 Apthera IOL (known as the IC-8 IOL in global markets) is approved in the United States for the treatment of cataracts. The lens received CE mark in 2015 and is available in Australia, New Zealand, Singapore, and select markets across Europe.
Led by Joseph C. Papa, CEO, Bausch + Lomb is dedicated to protecting and enhancing sight for millions of people around the world. Its portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments.
Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries.